A part of Merck

MAB3420 | Anti-Tau-1 Antibody, clone PC1C6

MAB3420
100 µg  
Recuperando precio...
No pudo obtenerse el precio
La cantidad mínima tiene que ser múltiplo de
Al finalizar el pedido Más información
Ahorró ()
 
Solicitar precio
Disponibilidad a confirmarDisponibilidad a confirmar
En existencia 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente

      Ofertas especiales

       

      Póngase en contacto con el Servicio de Atención al Cliente

      Click To Print This Page

      Descripción

      Replacement Information

      Ofertas especiales

      Tabla espec. clave

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      B, H, R IHC, WB M Purified Monoclonal Antibody
      Description
      Catalogue NumberMAB3420
      ReplacesAB1512
      Brand Family Chemicon®
      Trade Name
      • Chemicon
      DescriptionAnti-Tau-1 Antibody, clone PC1C6
      Background InformationTau, a microtubulebinding protein which serves to stabilize microtubules in growing axons, is found to be hyperphosphorylated in paired helical filaments (PHF), the major fibrous component of neurofibrillary lesions associated with Alzheimer’s disease. Hyperphosphorylation of Tau is thought to be the critical event leading to the assembly of PHF. Six Tau protein isoforms have been identified, all of which are phosphorylated by glycogen synthase kinase 3 (GSK 3). Cellular and subcellular localization: In situ, anti-tau-1 has a stringent specificity for the axons of neurons. The antibody does not stain the cell bodies or dendrites of neurons, nor does it stain any other cell type (4). However, this in vivo intracellular specificity is not maintained in culture: anti-tau-1 stains the axon, cell bodies, and dendrites of rat hippocampal neurons grown in culture (5). The specificity of anti-tau-1 was originally thought to represent the restricted expression of tau to axons. Later studies revealed that this specificity is dependant on the state of phosphorylation. In dephosphorylated samples (samples treated with alkaline phosphatase) anti-tau-1 stains astrocytes, perineuronal glial cells, and the axons, cell bodies and dendrites of neurons, while in untreated samples, anti-tau-1 stains only axons (6). (The epitope recognized by anti-tau-1 is probably at or near a phosphorylated site.)
      References
      Product Information
      FormatPurified
      Control
      • Alzheimer's brain tissue (dephosphorylation with alkaline phosphatase is recommended for staining neurofibrillary tangles in Alzheimer’s brain tissue) or human T98G glioblastoma cells
      Presentation0.02M phosphate buffer, pH 7.6, 0.25M NaCl, and 0.1% sodium azide
      Applications
      ApplicationAnti-Tau-1 Antibody, clone PC1C6 is an antibody against Tau-1 for use in IH & WB with more than 65 product citations.
      Key Applications
      • Immunohistochemistry
      • Western Blotting
      Application NotesWestern blot: Bovine brain microtubule proteins purified by two cycles of assembly and disassembly (9) are dissolved in SDS-PAGE sample buffer. Five micrograms of the microtuble preparation per lane is loaded onto a 4% to 20% SDS-PAGE gradient gel along side molecular weight markers (14.3 - 200 kD). After separation by electrophoresis, the proteins are blotted onto nitrocellulose. Tau is detected as a series of 5 bands (52-68 kD) with approximately 5 ng/mL of anti-tau-1.

      Immunohistochemistry: 5 μg/mL; stains axons in tissue primarily, however in culture Tau expression is not restricted to just axons.

      Optimal working dilutions must be determined by end user.

      Immunohistochemistry Protocol

      Dephosphorylation of tissue sections (optional)

      Dephosphorylation with alkaline phosphatase is recommended for staining neurofibrillary tangles in Alzheimer's brain tissue with anti-tau-1 (6). This treatment changes the staining pattern of anti-tau-1 to include cell bodies, dendrites and axons of neurons. In untreated samples, anti-tau-1 stains axons only.

      1. Incubate tissue sections at +32°C for 2.5 hours with constant agitation in the following solution: 100 mM Tris-HCl, pH 8.0; 130 units/mL alkaline phosphatase, 1 mM PMSF, 10 μg/mL pepstatin and 10 μg/mL leupeptin.

      2. Rinse sections twice, 3 min per rinse, with 100 mM Tris-HCl, pH 8.0.

      Anti-tau-1 staining

      1. Block non-specific binding by incubating sections in PBS containing 1% (v/v) normal animal serum, and 0.03% (w/v) Triton X-100. The animal serum should be from the same species as the secondary antibody.

      2. Rinse 3 times with PBS, 3 min per rinse.

      3. Incubate sections with anti-tau-1, approximately 5 μg/mL, diluted in PBS containing 1% (v/v) normal animal serum.

      4. Wash with PBS, changing the solution 3 times over a 3 min period.

      5. Detect with a standard secondary antibody detection system (10-13).
      Biological Information
      ImmunogenPurified denatured bovine microtubule associated proteins.
      ClonePC1C6
      ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
      HostMouse
      SpecificityBinds to all known electrophoretic species of tau in human, rat and bovine brain (one-dimensional SDS-PAGE). However there is some unphosphorylated bias with clone PC1C6 as it seem to recognize only dephosphorylated serine sites at 195, 198, 199, and 202 {Szendrei, et al 1993; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi-cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=7680727}. Also see Billingsley & Kincaid, 1997 Biochem J 323:577-591 for additional mapping information on PC1C6.
      IsotypeIgG2a
      Species Reactivity
      • Bovine
      • Human
      • Rat
      Antibody TypeMonoclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryThis gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy.
      Gene Symbol
      • MAPT
      • MTBT2
      • MAPTL
      • tau
      • FTDP-17
      • MSTD
      • TAU
      • FLJ31424
      • MTBT1
      • PHF-tau
      • DDPAC
      • MGC138549
      • PPND
      Purification MethodProtein A Purfied
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: P10636 # Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N- terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.
      SIZE: 758 amino acids; 78878 Da
      SUBUNIT: Interacts with PSMC2 through SQSTM1 (By similarity). Interacts with SQSTM1 when polyubiquitinated.
      SUBCELLULAR LOCATION: Cytoplasm, cytosol. Cell membrane. Note=Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.
      TISSUE SPECIFICITY: Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.DEVELOPMENTAL STAGE: Four-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) tau is found in both adult and fetal brain.
      DOMAIN: SwissProt: P10636 The tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats.
      PTM: Phosphorylation at serine and threonine residues in S-P or T- P motifs by proline-directed protein kinases (PDPK: CDC2, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in PHF-tau), and at serine residues in K- X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser- 622, Ser-641 and Ser-673 in several isoforms during mitosis. & Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur. & Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.
      DISEASE: SwissProt: P10636 # In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU). & Defects in MAPT are a cause of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP17) [MIM:600274, 172700]; also called frontotemporal dementia (FTD) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons. & Defects in MAPT are a cause of pallido-ponto-nigral degeneration (PPND) [MIM:168610]. The clinical features include ocular motility abnormalities, dystonia and urinary incontinence, besides progressive parkinsonism and dementia. & Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease. & Defects in MAPT are a cause of progressive supranuclear palsy (PSP) [MIM:601104, 260540]; also known as Steele-Richardson- Olszewski syndrome. PSP is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613. & Defects in MAPT may be a cause of hereditary dysphasic disinhibition dementia (HDDD) [MIM:607485]. HDDD is a frontotemporal dementia characterized by progressive cognitive deficits with memory loss and personality changes, severe dysphasic disturbances leading to mutism, and hyperphagia.
      SIMILARITY: Contains 4 Tau/MAP repeats.
      Molecular Weight5 bands (52–68 kDa)
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsMaintain for 1 year at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
      Packaging Information
      Material Size100 µg
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      Ficha datos de seguridad (MSDS)

      Título

      Ficha técnica de seguridad del material (MSDS) 

      Certificados de análisis

      CargoNúmero de lote
      Anti-Tau-1, clone PC1C6 - 2370726 2370726
      Anti-Tau-1, clone PC1C6 - 2428670 2428670
      Anti-Tau-1, clone PC1C6 - 2455695 2455695
      Anti-Tau-1, clone PC1C6 - 2463638 2463638
      Anti-Tau-1, clone PC1C6 - 1958299 1958299
      Anti-Tau-1, clone PC1C6 - 1990418 1990418
      Anti-Tau-1, clone PC1C6 - 2015983 2015983
      Anti-Tau-1, clone PC1C6 - 2064711 2064711
      Anti-Tau-1, clone PC1C6 - 2211033 2211033
      Anti-Tau-1, clone PC1C6 - 2296738 2296738
      Anti-Tau-1, clone PC1C6 - LV1616764 LV1616764
      Anti-Tau-1, clone PC1C6 - LV1739991 LV1739991
      Anti-Tau-1, clone PC1C6 - LV1786429 LV1786429
      Anti-Tau-1, clone PC1C6 - NG1743745 NG1743745
      Anti-Tau-1, clone PC1C6 - NG1920468 NG1920468
      Anti-Tau-1, clone PC1C6 -2517798 2517798
      Anti-Tau-1, clone PC1C6 -2549403 2549403
      Anti-Tau-1, clone PC1C6 -2580635 2580635
      Anti-Tau-1, clone PC1C6 -2621506 2621506
      Anti-Tau-1, clone PC1C6 -2683924 2683924
      Anti-Tau-1, clone PC1C6 -2721720 2721720
      Anti-Tau-1, clone PC1C6 -2768444 2768444

      Referencias bibliográficas | 94 Disponible | Ver todas las referencias

      Visión general referenciasAplicación EspeciePub Med ID
      Coupled local translation and degradation regulate growth cone collapse.
      Deglincerti, A; Liu, Y; Colak, D; Hengst, U; Xu, G; Jaffrey, SR
      Nature communications 6 6888 2015

      Mostrar resumen
      25901863 25901863
      Structural basis for extracellular cis and trans RPTPσ signal competition in synaptogenesis.
      Coles, CH; Mitakidis, N; Zhang, P; Elegheert, J; Lu, W; Stoker, AW; Nakagawa, T; Craig, AM; Jones, EY; Aricescu, AR
      Nature communications 5 5209 2014

      Mostrar resumen
      25385546 25385546
      AAV-mediated overexpression of neuroserpin in the hippocampus decreases PSD-95 expression but does not affect hippocampal-dependent learning and memory.
      Tsang, VW; Young, D; During, MJ; Birch, NP
      PloS one 9 e91050 2014

      Mostrar resumen
      24608243 24608243
      Specificity of anti-tau antibodies when analyzing mice models of Alzheimer's disease: problems and solutions.
      Petry, FR; Pelletier, J; Bretteville, A; Morin, F; Calon, F; Hébert, SS; Whittington, RA; Planel, E
      PloS one 9 e94251 2014

      Mostrar resumen
      24788298 24788298
      Gαz regulates BDNF-induction of axon growth in cortical neurons.
      Hultman, R; Kumari, U; Michel, N; Casey, PJ
      Molecular and cellular neurosciences 58 53-61 2014

      Mostrar resumen
      24321455 24321455
      MHC class I limits hippocampal synapse density by inhibiting neuronal insulin receptor signaling.
      Dixon-Salazar, TJ; Fourgeaud, L; Tyler, CM; Poole, JR; Park, JJ; Boulanger, LM
      The Journal of neuroscience : the official journal of the Society for Neuroscience 34 11844-56 2014

      Mostrar resumen
      25164678 25164678
      Regulation of axon growth by the JIP1-AKT axis.
      Dajas-Bailador, F; Bantounas, I; Jones, EV; Whitmarsh, AJ
      Journal of cell science 127 230-9 2014

      Mostrar resumen
      24198394 24198394
      Improved application of the electrophoretic tissue clearing technology, CLARITY, to intact solid organs including brain, pancreas, liver, kidney, lung, and intestine.
      Lee, H; Park, JH; Seo, I; Park, SH; Kim, S
      BMC developmental biology 14 48 2014

      Mostrar resumen
      25528649 25528649
      Rapid accumulation of endogenous tau oligomers in a rat model of traumatic brain injury: possible link between traumatic brain injury and sporadic tauopathies.
      Hawkins, BE; Krishnamurthy, S; Castillo-Carranza, DL; Sengupta, U; Prough, DS; Jackson, GR; DeWitt, DS; Kayed, R
      The Journal of biological chemistry 288 17042-50 2013

      Mostrar resumen
      Immunoblotting (Western)Human23632019 23632019
      A novel Hap1-Tsc1 interaction regulates neuronal mTORC1 signaling and morphogenesis in the brain.
      Mejia, LA; Litterman, N; Ikeuchi, Y; de la Torre-Ubieta, L; Bennett, EJ; Zhang, C; Harper, JW; Bonni, A
      The Journal of neuroscience : the official journal of the Society for Neuroscience 33 18015-21 2013

      Mostrar resumen
      24227713 24227713

      Ficha técnica

      Cargo
      Anti-Tau-1, clone PC1C6 - Data Sheet

      Newsletters / Publications

      Title
      Research Focus - Volume 2, 2013

      Productos y aplicaciones relacionados

      Familias de productos

      View Gene Related Products for this Target

      Categorías

      Life Science Research > Antibodies and Assays > Primary Antibodies